



Olympus Corporation

Company Presentation

Disclaimer:

- Any content or information (“Content”) presented herein is illustrative in nature and does not guarantee or represent specific information, outcomes or results.
- Under no circumstances shall Olympus or its employees, consultants, agents or representatives be liable for any costs, expenses, losses, claims, liabilities, or other damages (whether direct, indirect, special, incidental, consequential, or otherwise) that may arise from, or be incurred in connection with, the Content or any use thereof.

OLYMPUS

A couple is seen from behind, standing on a grassy mountain ridge. They are looking out over a vast, scenic landscape of rolling hills and mountains under a bright blue sky filled with fluffy white clouds. The scene is bathed in warm, golden light, suggesting late afternoon or early morning. The couple is dressed in dark clothing, and their silhouettes are clearly visible against the bright background.

True to Life

"True to Life" is our global brand message that expresses Olympus's commitment to Our Purpose.

At Olympus, we believe everyone should have the opportunity to live life to the full. Every day we are advancing medical technology solutions to help people everywhere fulfill their desires, their curiosity, their dreams, their ambitions, and their lives.

A woman with long dark hair, wearing a teal patterned top, is pointing at a glass wall covered in colorful sticky notes. A man with a shaved head, wearing a blue striped shirt, stands behind her, looking at the wall. The scene is set in a modern office environment with large windows in the background.

01 As a Globally Leading Medtech Company

02 Elevating the Standard of Care

03 For a Sustainable Society

04 Fostering a Healthy Organization

05 Company Information

06 Appendix: Olympus History



01

**As a Globally Leading Medtech
company**

A photograph of a woman with long brown hair hugging a young child from behind. The woman is smiling and looking towards the child. The child is wearing a dark, quilted jacket. The entire image has a blue tint. Overlaid on the left side is a large yellow quotation mark.

“

We will continue to make people's lives **healthier, safer, and more fulfilling.**

”

Our Contribution to Patients

1.9 million


**New Incidents of
Colon Cancer**

Source: GLOBOCAN 2020


50 million

**Colonoscopies Performed
Worldwide**

*Numbers of the US, Canada, Germany, France, Italy, Spain, the UK, Poland, Japan, China, South Korea, Australia, India, and Russia: As of 2019



Our Contribution to Patients



100



TOP 3

Diseases or Conditions Treated


At Olympus we have versatile medical devices with the ability to treat approximately 100* diseases or conditions

* As of March 2022


Cancers Treated

Olympus provides products/solutions for lung, colorectum and stomach
- Three cancers from the top 5* highest incidence of cancers

*Top 3 highest incidence of caners excluding breast and prostate cancer, as of March 2022.
Source: GLOBOCAN 2020



Making people's lives healthier, safer and more fulfilling



32,844

Employees Worldwide*1

*1: As of March 2023

38

Countries or Regions*2

*2: As of December 2022

Making people's lives healthier, safer and more fulfilling



¥881.9bn

Total Medical Revenue FY2023*

*Figures are fiscal year revenues as of
March 2023



70%

Global Market Share*

Olympus is the leader in
gastrointestinal endoscopic
equipment

*As of Oct 2022

Making people's lives healthier, safer and more fulfilling



TOP 100

Global Innovator

Since 2012 to 2020, and in 2022 and 2023, Olympus has been awarded as one of the top 100 most innovative companies in the world.

<https://clarivate.com/top-100-innovators/>



291

Awards

Since 1966, Olympus has been consistently honored with national and international design awards for its innovative product designs*

*As of March 2022



17,000

Patents

across our product portfolio*

*As of March 2022



CO2 "0"

Emissions by 2030

We set as a target of achieving net zero CO2 emissions by 2030 from our site operations

*As of March 2022

A photograph of two surgeons in an operating room, both wearing blue scrubs, blue bouffant caps, and white surgical masks. The surgeon on the right is also wearing glasses. The surgeon on the left is holding a surgical instrument. The background shows medical equipment and a blue-tinted environment.

02

Elevating the Standard of Care

We will focus on areas where we can have a market-leading impact

GI

GI Endoscopy
Market Share



55% of ESD*¹
revenue*³

GI Endotherapy
Market Share



30% of TSD*²
revenue*³

Urology

Market Share



35% of TSD*²
revenue*³

Respiratory

Market Share



15% of TSD*²
revenue*³

Note: Sub-segment sales ratios within ESD/TSD are figures of fiscal year 2023.
*1 ESD: Endoscopic Solutions Division
*2 TSD: Therapeutic Solutions Division
*3: Approx.

We aim to improve patient outcomes by elevating the standard of care in targeted disease states



1 million

Stomach cancer
New patients per year*

*Estimated. Epi Database®. Cerner Enviza.
Available from wee.epidb.com. Accessed 18 Nov
21. Data for USA, EU5, JP, CN



2nd

Colorectal cancer
Leading cause of cancer-related death


*GLOBOCAN 2020



60 million

Pancreaticobiliary diseases
Patients affected*

*Estimated. Epi Database®. Cerner Enviza.
Available from wee.epidb.com. Accessed 18 Nov
21. Data for USA, EU5, JP, CN



We aim to improve patient outcomes by elevating the standard of care in targeted disease states



1.5 million

Bladder cancer Patients*

*Estimated. Epi Database©. Cerner Enviza. Available from wee.epidb.com. Accessed 18 Nov 21. Data for USA, EU5, JP, CN



50%

BPH: Aged between 51 and 60 are affected*


*BPH: surgical management. – Urology Care Foundation website. www.urologyhealth.org. Updated July 2013.





13%

Urology stone management of population: rising prevalence*

*Epidemiology of stone disease across the world – World J Urol. 2017 Sep;35(9):1301-1320. doi: 10.1007/s00345-017-2008-6.



We aim to improve patient outcomes by elevating the standard of care in targeted disease states



1st

**Lung Cancer
Cause of cancer death***

*GLOBOCAN 2020



174 million

**COPD
Patients***


*Estimated. Epi Database®. Cerner Enviza.
Available from wee.epidb.com. Accessed 18 Nov
21. Data for USA, EU5, JP, CN

Our solutions in GI areas



Target disease states: Stomach cancer | Colorectal cancer | Pancreaticobiliary diseases



Our solution




Endoscopy system
for detection, diagnosis and staging

AI supported detection

Automatic real-time detection of suspicious tissues and lesions




Magnifying endoscopes



Ultrasound endoscopes

Versatile range of products for endotherapies

GI Endotherapy single-use devices for biopsy, ERCP¹, hemostasis, resection / dissection



¹ ERCP: Endoscopic retrograde cholangio pancreatography

Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.

Our solutions in urologic diseases



Target disease states: Urology stone management | BPH | Bladder cancer

Our solution

1 TUR is a procedure in which a surgeon inserts a resectoscope from the urethra and then, using the handle, operates a loop-shaped electrode to surgically resect tissue from an enlarged prostate or a bladder tumor with an electro-surgical knife. TURis is a procedure, in which a resection is performed by discharging electricity from the entire area surrounding the electrode through saline.

*Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.



Bladder Cancer




Urology stone management



BPH Treatment

Diagnosis



World-class endoscopic visualization technology




Treatment

TURis¹

Lithotripsy



Laser System contributes to break up stones faster and more completely than previous options



Lithotripsy system supports efficient percutaneous stone procedures

Implants



Minimally invasive, temporarily implanted device*

Resection



Advanced energy system

Enucleation



Complete suite of lasers for enucleation of enlarged prostates

Our solution for respiratory diseases



Target disease states: Lung cancer | COPD | Air leaks, etc.


Our solution

1 EBUS: Endobronchial ultrasound
2 EBUS-TBNA: Endobronchial ultrasound-guided transbronchial needle aspirations
3 The device is approved as Humanitarian Device Exemption. Authorized by Federal law for use in the trademark of air leaks. The effectiveness of this device for this use has not been demonstrated.

*Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.



COPD
Air leaks




Other four areas that make standard of care contributions

Surgical Endoscopy



Surgical endoscopy systems

Surgical Devices



Energy devices

ENT



Rhino-Laryngo
videoscope

Gynecology



Rigid endoscope
(Telescope)

A woman and two young girls are sitting on the grass in a garden, planting small green seedlings. The woman is smiling and looking down at the plants. The girls are focused on their task. The scene is overlaid with a blue tint.

03

For a Sustainable Society

Common Topics in ESG*



Environment

- Climate Change / Carbon Neutrality
- Circular Economy
- GHG Emissions
- Water & waste management



Social

- Human Rights
- Diversity, equality and inclusion
- Workplace safety
- Healthcare Access & Outcome



Governance

- Corporate Risk Management
- Management Structure
- Board Structure and Diversity
- Reporting Transparency

*Major examples only / not limited

Our Engagement on ESG



We will actively engage on six ESG areas



Our materiality

- Healthcare access and outcomes
- Compliance, product quality and safety
- Responsible supply chain
- Diversity and inclusion
- Carbon neutral society and circular economy

Healthcare Access and Outcomes

To Elevate the Standard of Care

- We strengthen the Olympus Group's functional capabilities to support the development of safer, more effective, and innovative patient-centered medical devices
- We develop and implement educational programs and training for healthcare professionals to rapidly gain technical expertise and achieve excellent clinical results while ensuring the patient's safety.

1,285

Number of "Olympus Continuum" trainings held

Over
335

Number of organizations that received Olympus Grants




Compliance, Product Quality and Safety

Compliance


- The Olympus Global Code of Conduct, adopted in 2019. It continuously assess whether business activities are consistent with applicable legal requirements and Company policies and procedures

Product Quality and Safety

- The QA function introduced new Field Corrective Action, Corrective and Preventive Action (CAPA) processes that are consistent across all global regions, as well as digital solutions that were deployed globally.



Attendance rate of Olympus Group employees in Japan receiving education on compliance helpline



Companywide document reduction rate due to process efficiency

Responsible Supply Chain

Procurement

- We Olympus publish “Global Standards: What Olympus Expects of Third Parties” to show its basic requirements to all third parties that support its business activities
- We have also adopted the “Request to Suppliers,” a document defining its expectations toward suppliers in such areas as respect for human rights, compliance with laws, regulations and social norms.

Human Rights

- We implemented online training on basic information regarding human rights and the UN Guiding Principles for Olympus Group employees in Japan.



Conducted a web-based corporate survey*
*Administered to suppliers engaged in business at Olympus offices in Japan



Given copies of “Request to Suppliers”
*Covering the major direct materials suppliers engaged in business at Olympus offices in Japan



Attendance ratio for online training regarding human rights for Olympus Group employees in Japan



Diversity and Inclusion

Expanding Globally Integrated HR Management

- We established the system that enables optimal talent allocation at the global level.

Promoting the Advancement of Women

- To encourage appointing female managers, we conduct training program to enhance participants' skills and capacities, and to nurture managerial mindsets.

Aiming for a Diverse Workforce

- We employ people with disabilities and to provide ongoing work-related support and training. We promote understanding and support for sexual minorities.



Global percentage of non-Japanese in managerial positions in Olympus Group*

*The percentage within global senior management as of July 1, 2022



Global percentage of females in managerial positions in Olympus Group*



Increase in number of "females in managers" of the Olympus Group in Japan: between March 2016 and April 2022



Carbon Neutral Society and Circular Economy

To archive a target of carbon neutrality

- We set a target of carbon neutrality by 2030 for its site operation
- We will switch electricity procurement for its site operations* to renewable energy sources also by 2030.

*Excluding rental properties, such as sales sites

	Results			Targets
	FY2020	FY2021	FY2022	FY2031
CO2 emissions	Reduced by 9.9% compared to FY2018	Reduced by 23.3% compared to FY2018	Reduced by 25.9% compared to FY2018	Carbon neutrality for Olympus' site operation
Renewable energy rate	11.4%	12.2%	18.9%	100%






04

Fostering a Healthy Organization

An Evolution in Corporate Culture



The six dimensions necessary to achieve a Healthy Organization and Our Core Values


Healthy Organization

We define our aim for a Healthy Organization as “Committed to delivering Olympus’ Purpose by creating a working culture where everyone is empowered to perform their best” and we consider there to be six dimensions which is necessary to bring it to fruition. We are currently advancing initiatives at the global level to further improve those six dimensions.

Core Value Survey

The Olympus Core Values Survey represents an important employee engagement tool that supports our aim to create a Healthy Organization. This survey is conducted in every 2 years.


And we conduct employee pulse check every year and aimed to track the impact and progress of the actions we derived from last year's Global Core Values Survey (GCVS), to check if we are right on track to further improve enablement, engagement, and to support retention of our employees.



As of Nov. 2022

Helpful Tools and Practices to Support Our Journey

INTERNAL USE ONLY



The six dimensions necessary to achieve a Healthy Organization and Our Core Values


■ Key issues addressed

Health Initiatives

Description

- | Health Initiatives | Description |
|---------------------------------------|--|
| 1 Olympus exchange | Cross-functional exchange of knowledge; improves understanding in areas out of own organization, and Olympus' business etc. |
| 2 Onboarding | Contents enable new joiners for better cross collaboration, and contents enable first experience in global projects or environment |
| 3 Community building | Enable colleagues to develop communities to increase cross-collaboration & networking |
| 4 Micro-habits to encourage challenge | Encourages failure learning mindset through adopting micro-habits and sharing best practices |
| 5 Meeting norms | Approach and tools intended to improve meeting efficiency and decrease unnecessary meetings |
| 6 Team Build | Approach involves learning and reflection to improve understanding and create a comfortable environment within team |
| 7 1 on 1 | Approach ensure managers and members regularly interact, support growth of members and raise performance as result |
| 8 5-minute feedback | A short and timely casual session to encourage two-way feedback |

Follow-up Measures for Our Core Values Survey



Gemba Visit

Management visit Factory and R&D to close the gap between management and staff. Management members gain insight into the current situation that is useful for making decisions and a collaborator in leading the company.

6,000

Global Program

We are providing training to all employees worldwide to strengthen their business and execution since we believe this is a key factor for ensuring organizational change.

No. of participants*

4,300

Global Communication Skill Strengthening Program

In Japan, we are undertaking the Global Communication Skill Strengthening Program to improve English proficiency and support cross-cultural understanding.

No. of participants*

*2020-2022 As of Nov 2022

05

Company Information



Company Outline

Company Name	Olympus Corporation
Market	Tokyo Stock Exchange (7733)
Established	October 12, 1919
Director, Representative Executive Officer, President and CEO	Stefan Kaufmann
Head Office	Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan
Share Capital	124.643 billion yen (As of March 31, 2023)
Consolidated Revenue	881.9 billion yen (Fiscal year ended March 31, 2023)
Consolidated Headcount	32,844 (As of March 31, 2023)



Executive Officers



Yasuo Takeuchi

Director, Representative
Executive Officer, and
Executive Chairman and
ESG Officer



Stefan Kaufmann

Director, Representative
Executive Officer, President and
Chief Executive Officer



Frank Drewalowski

Executive Officer and
Endoscopic Solutions
Division Head



Gabriela Kaynor

Executive Officer and
Therapeutic Solutions
Division Head



Chikashi Takeda

Executive Officer,
Chief Financial Officer



Nacho Abia

Executive Officer and
Chief Strategy Officer



Tetsuo Kobayashi

Executive Officer,
Chief Manufacturing
and Supply Officer



Andre Roggan

Executive Officer,
Chief Technology Officer



Shigeto Ohtsuki


Executive Officer and Chief
Human Resources Officer



Pierre Boisier

Executive Officer and
Chief Quality Officer

Revenue by Business Divisions




Life Science Solutions and Industrial Solutions are being operated by Evident Corporation as of April 1st, 2022.

Revenue by Region




¥881.9bn


March 2023 *Approx.




¥122.5bn




¥322.2bn




¥222.2bn



¥117.1bn





¥77.8bn




¥20.2bn


Revenue and Operating Profit



Endoscopic Solutions
63%



Therapeutic Solutions
36%



Note) We split off the imaging business to a special purpose company established by Japan Industrial Partners, Inc. on January 1, 2021. In this regard, imaging division is categorized as a discontinued operation, effective Q2 of FY2021 and figures of FY2020 is restated.

*Due to rounding, the total may not add up to 100%



06

Appendix: Olympus History

Olympus History



Sales launch of **Asahi** microscope.

1920



Launch of **Showa GK** immersion microscope.

1927



Renaming of company to **Olympus Optical Co., Ltd.**

1949



Launch of the **GT-I** gastrocamera.

1952



1919

Founding of **Olympus** by Takeshi Yamashita under the company name **Takachiho Seisakusho**; established in Tokyo, Japan, for domestic production of microscopes.



1921

Registration of **Olympus name** as a trademark.



1936

Launch of first Olympus camera, the **Semi-Olympus I**, after development of Zuiko photographic lenses.

1950

Development of world's **first practical** gastrocamera.



1959

Launch of **Olympus PEN**, an innovative half-frame film camera.

Olympus History

Launch of **GTF™** gastrocamera with fiberoptic.

Establishment of **Olympus Corporation of America** as a sales subsidiary for microscopes and medical equipment in the United States.

Launch of **OM-1**, a compact, lightweight, SLR camera, which was initially named M-1.

Establishment of **Olympus Camera Corporation** as a sales base in the United States.



1964



1968



1972



1977



1964



1966



1969



1975

1979

Start up of **Olympus Optical Co.** in Hamburg, Germany, as Olympus' European headquarters.

Launch of **GFS** gastrofiberscope, which didn't have a camera mechanism on the tip.

Introduction of **ZUIKO PEARLCORDER™** recorder, the world's first microcassette tape recorder.

Collaboration with Winter & Ibe GmbH to produce surgical rigid medical endoscopes, with Olympus supplying the optical systems.

Opening of the **National Service Center** in San Jose, California, for U.S.-based Olympus equipment repairs.

Olympus History



Launch of **BH2** microscope series.

1980

Development of **OES** (Olympus Endoscopy System).

1983

Merger of two U.S. sales units to form the North American subsidiary, Olympus Corporation.

1983



Acquisition of British company **KeyMed Ltd.** as an Olympus subsidiary.

1987

Launch of **EVIS™100** (1989) and **200** (1990) endoscopic video information systems.

1990



1979

Acquired **Winter & Ibe GmbH** to establish Olympus Winter & Ibe for the production and supply of surgical endoscopes and instruments.



1980

Development of an Olympus ultrasound endoscope system.



1983

Launch of **AH2** microscope series, the world's first microscope with autofocus functionality.

1985

Introduction of Olympus' endoscopic video information system.



1987

Establishment of the Beijing office to market microscopes and endoscopes in China.



1991

Launch of first μ [mju:] / Infinity Stylus camera.

Olympus History

Launch of **BX** series of biological microscopes and UIS series of object lenses, which improved product appeal in the AX, BX, CX, and IX series of microscopes.

1993



Launch of **C-800L/D-300L** and **C-400L/D-200L**, Olympus' first consumer digital cameras.

1996



Launch of **MX50** semiconductor inspection microscope.

1996



Introduction of **IPLEX™** industrial videoscope system.

2001



1995
Establishment of **Olympus Endo-Repair Europa GmbH**, endoscope repair service center for the European market, in Hamburg, Germany.

1996
Launch of **FLUOVIEW™** confocal laser scanning biological microscope.

2000
Introduction of **EVIS EXERA™** series endoscopic video system.



2002
Launch of **VISERA™** series, an integrated video system for surgery.

Olympus History



Launch of electrosurgical **Itknife™** device.

2002



Renaming of company to Olympus Corporation.

2003



Launch of **FLUOVIEW™ FV1000** system, the world's first laser scanning microscope with two independent scanners.

2004



Opening of Shirakawa Medical Equipment Service Operation Center (SORC Shirakawa) in Japan.

2005



2002

Launch of **EVIS LUCERA™** system, the world's first high-definition endoscopic video system.

2003

Launch of **E-1** digital SLR camera with interchangeable lenses.

2004

Launch of **LEXT™ OLS3000** microscope, the first in the LEXT 3D confocal laser microscope series.



2005

Acquisition of **R/D Tech Inc.** to expand the nondestructive testing device business.



Olympus History

Launch of **EVIS EXERA II™** and **EVIS LUCERA SPECTRUM** endoscopic video systems.

2006



Merger with **Gyrus PLC** to deliver additional technology and sales/marketing knowhow to the Olympus surgical business.

2008



Launch of **EPOCH1000** series ultrasonic flaw detectors.

2009



Launch of **BX3** system biological microscope.

2010



Acquisition of **Innov-X Systems, Inc.** to expand Olympus' presence in nondestructive testing.

2010



2006

Opening of Shanghai Medical Equipment Service Operation Center (SORC Shanghai) in China.



2008

Establishment of **Olympus Vietnam Co., Ltd.** manufacturing facility for cameras and medical equipment.



2009


Launch of **Olympus PEN E-P1** mirrorless camera.



2010

Formation of **OSTE**, Olympus Surgical Technologies Europe.

Olympus History



Launch of **VISERA ELITE** integrated surgical video endoscope system.

2011

Formation of **OSTA**, Olympus Surgical Technologies America.

2012

Launch of **THUNDERBEAT**, an integrated surgical energy device.

2012

Launch of **EVIS LUCERA ELITE** system and **EVIS EXERA III** system.

2012



2012

Launch of **OM-D E-M5** mirrorless camera.



2012

Announcement of Olympus' medium-term vision, designed to realize a "New Olympus" and take the Company "Back to Basics."



2013

Launch of **OM-D E-M1** mirrorless camera.

2011

Launch of **OmniScan MX2**, a phased array flaw detector.



2012

Formation of a third-party committee by Olympus to investigate prior concealment of company losses.



Olympus History



Launch of
OM-D E-M1 Mark II.

2016



2015

Introduction of a **surgical endoscope system with 4K** resolution based on technology developed by Sony Olympus Medical Solutions Inc.



Launch of **ORBEYE™** Surgical microscope, incorporating the latest advances in 4K 3D video technology.

2017



2016

Launch of **VANTA** series, a range of handheld XRF analyzers.

Celebration of Olympus
100th Anniversary.

2019



2018

Introduction of new **Corporate Philosophy.**



Transfer of
Imaging Business

2021

2020

Launch of **EVIS X1™** System for EMEA and some Asian countries/regions*



Transfer of
Scientific Business

2023

2022

Launch of **VISERA ELITE III** Surgical Visualization Platform for EMEA and some Asian countries/regions*

*Not Available for Sale in the United States

OLYMPUS

A thick, yellow, brushstroke-style underline that tapers at both ends, positioned directly beneath the word "OLYMPUS".

Olympus is a registered trademark of Olympus Corporation, Olympus America Inc., and/or their affiliates.